Skip to main content

Table 2 Clinical and Biological Characteristics of the Eligible Patients

From: Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial

Parameter

Total

no-Ara-c group

Ara-c group

P

N

66

35

30

 

Age, years

 Median

8

8.0

8

0.119

 Range

2–14.0

2–14.0

2–13.0

 

Gender

   

0.749

 Male

43

22

20

 

 Female

23

13

10

 

WBC count, 109/L

   

0.220

 Median

4.71

5.74

4.23

 

 Range

0.82–202.4

0.82–202.4

0.99–130

 

WBC ≤ 10 × 109/L (n, %)

44 (66.7%)

22 (62.9%)

22 (73.3%)

0.362

WBC > 10 × 109/L (n, %)

22 (33.3%)

13 (37.1%)

8 (26.7%)

 

Haemoglobin count, g/L

   

0.075

 Median

79

81.5

78

 

 Range

44–127

49–127

44–124

 

Platelet count, 109/L

   

0.418

 Median

30.5

32.0

24.5

 

 Range

2–130

6–130

2–125

 

PML-RARA

   

0.846

 Long transcript

26

13

12

 

 Short transcript

17

8

9

 

 Variable

9

6

4

 

 Not done

14

8

5

Â